Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia

Gómez-Gómez,Yazmín; Organista-Nava,Jorge; Rangel-Rodriguez,Carlos   Alberto; Illades-Aguiar,Berenice; Moreno-Godínez,María   Elena; Alarcón‑Romero,Luz  Del Carmen; Leyva-Vázquez,Marco   Antonio

doi:10.3892/ol.2014.2175

August-2014 Volume 8 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2014 Volume 8 Issue 2

Full Size Image

Article

Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia

Authors:
- Yazmín Gómez-Gómez
- Jorge Organista-Nava
- Carlos Alberto Rangel-Rodriguez
- Berenice Illades-Aguiar
- María Elena Moreno-Godínez
- Luz Del Carmen Alarcón‑Romero
- Marco Antonio Leyva-Vázquez
View Affiliations / Copyright

Affiliations: Institute of Cellular Physiology, National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico, Laboratory of Molecular Biomedicine, School of Biological Sciences, Guerrero State University, Chilpancingo, Guerrero 39090, Mexico, Laboratory of Toxicology and Environmental Health, School of Biological Sciences, Guerrero State University, Chilpancingo, Guerrero 39090, Mexico, Laboratory of Cytopathology, School of Biological Sciences, Guerrero State University, Chilpancingo, Guerrero 39090, Mexico
Pages: 731-735
|
Published online on: May 26, 2014

https://doi.org/10.3892/ol.2014.2175
Expand metrics +

Abstract

Folylpolyglutamate synthase (FPGS) is the key enzyme that converts the chemotherapeutic agent, methotrexate (MTX), into MTX polyglutamate. An A22G polymorphism has been found in the FPGS gene. This study aimed to evaluated whether the A22G polymorphism in the FPGS gene is associated with an increased risk of acute lymphoblastic leukemia (ALL) and whether it plays a role in increasing the survival of patients with ALL. In this study, a total of 70 patients with ALL and 100 healthy individuals were genotyped by polymerase chain reaction and sequencing methods. The homozygous variant, 22G/G [odds ratio (OR)=3.88; 95% confidence interval (CI): 2.50‑6.03] and the heterozygous variant, 22A̸G (OR=1.37; 95% CI: 1.26‑48.95) were risk factors for ALL. Patients with the 22A̸G genotype had an OR of 1.81 (95% CI: 1.57‑5.74; P=0.049) and carriers of the 22G̸G genotype had an OR of 2.44 (95% CI: 2.40‑11.82; P=0.017) for relapse. A significant association between the A22G polymorphism and survival of patients with ALL was found (P<0.05); whereas, individuals with A̸G or G̸G genotypes had a decreased overall survival (log‑rank test, P=0.044). Although preliminary, these data suggest that the genotypes of the A22G polymorphism may be risk factors for ALL and may play a role in the survival of patients with ALL.

View Figures

View References

1	Daniel-Cravioto A, Gonzalez-Bonilla CR, Mejia-Arangure JM, et al: Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City. Leuk Lymphoma. 50:1352–1360. 2009.
2	Mejia-Arangure J, Bonilla M, Lorenzana R, et al: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer. 5:332005.
3	Database of Deaths National Institute of Statistics (INEGI)/Health Secretariat (SSA). Directorate General of Health Information; Mexico: February. 2006, Available at: www.inegi.org.mx/urisimplewww.inegi.org.mx/. Accessed April, 2008
4	Leil TA, Endo C, Adjei AA, et al: Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res. 67:8772–8782. 2007.
5	Gómez-Gómez Y, Organista-Nava J, Saavedra-Herrera MV, et al: Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms. Exp Ther Med. 3:665–672. 2012.
6	Insurance-Popular. Secretary of Health/Seguro Popular. http://www.seguro-popular.gob.mx/. Accessed May, 2009
7	Leyva-Vázquez MA, Organista-Nava J, Gómez-Gómez Y, et al: Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia. J Investig Med. 60:1064–1067. 2012.
8	Merante F, Raha S, Reed J and Proteau G: The Simultaneous Isolation of RNA and DNA from Tissues and Cultured Cells. Methods Mol Biol. 58:3–9. 1996.
9	Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, et al: Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res. 34:728–732. 2010.
10	Dulucq S, St-Onge G, Gagné V, et al: DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 111:3692–3700. 2008.
11	Wessels JA, van der Kooij SM, le Cessie S, et al: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56:1765–1775. 2007.
12	Lee KM, Lan Q, Kricker A, et al: One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet. 122:525–533. 2007.
13	Lim U, Wang SS, Hartge P, et al: Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood. 109:3050–3059. 2007.
14	van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK, et al: Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics. 8:141–150. 2007.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles